bioRxiv preprint doi: https://doi.org/10.1101/2022.10.13.512134; this version posted January 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

1	Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1
2	Omicron
3	Da-Yuan Chen ^{1,2} , Devin Kenney ^{2,3} , Chue Vin Chin ^{1,2} , Alexander H. Tavares ^{1,2} , Nazimuddin
4	Khan ^{1,2} , Hasahn L. Conway ^{1,2} , GuanQun Liu ⁴ , Manish C. Choudhary ^{5,6} , Hans P. Gertje ² , Aoife
5	K. O'Connell ² , Darrell N. Kotton ^{7,8} , Alexandra Herrmann ⁹ , Armin Ensser ⁹ , John H. Connor ^{2,3} ,
6	Markus Bosmann ^{10,11,12} , Jonathan Z. Li ^{5,6} , Michaela U. Gack ⁴ , Susan C. Baker ¹³ , Robert N.
7	Kirchdoerfer ¹⁴ , Yachana Kataria ¹¹ , Nicholas A. Crossland ^{2,11} , Florian Douam ^{2,3} , Mohsan
8	Saeed ^{1,2#}
9	
10	1. Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA
11	2. National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA,
12	USA
13	3. Department of Microbiology, Boston University School of Medicine, Boston, MA, USA
14	4. Cleveland Clinic Florida Research and Innovation Center, Port St. Lucie, FL, USA
15	5. Brigham and Women's Hospital, Boston, MA, USA
16	6. Harvard Medical School, Cambridge, MA, USA
17	7. Center for Regenerative Medicine of Boston University and Boston Medical Center,
18	Boston, MA, USA
19	8. The Pulmonary Center and Department of Medicine, Boston University School of
20	Medicine, Boston, MA, USA

01	0	lo atituda af			\/:neleeu.			منعم ومعاد المنا	Entra alutia la
21	9.	institute of	Clinical and	a iviolecular	virology,	University	/ HOS	pital Erlangen,	Friedrich-

- 22 Alexander Universität Erlangen-Nürnberg, Erlangen, Germany
- 23 10. Pulmonary Center, Boston University School of Medicine, MA, USA
- 11. Department of Pathology and Laboratory Medicine, Boston University School of

25 Medicine, MA, USA

- 12. Center for Thrombosis and Hemostasis, University Medical Center of the Johannes
 Gutenberg-University, Mainz, Germany
- 13. Department of Microbiology and Immunology, and Infectious Disease and Immunology
- 29 Research Institute, Stritch School of Medicine, Loyola University, Chicago, Maywood, IL,
- 30 USA
- 14. Department of Biochemistry, College of Agricultural and Life Sciences, University of
 Wisconsin, Madison, WI, USA
- 33 **Correspondence: msaeed1@bu.edu
- 34
- 34
- 35
- _
- 36
- 37
- 20
- 38
- 39
- 40
- 41
- 42 Abstract

43 The recently identified, globally predominant SARS-CoV-2 Omicron variant (BA.1) is 44 highly transmissible, even in fully vaccinated individuals, and causes attenuated disease compared with other major viral variants recognized to date¹⁻⁷. The Omicron spike (S) protein, 45 46 with an unusually large number of mutations, is considered the major driver of these phenotypes^{3,8}. We generated chimeric recombinant SARS-CoV-2 encoding the S gene of 47 48 Omicron in the backbone of an ancestral SARS-CoV-2 isolate and compared this virus with the 49 naturally circulating Omicron variant. The Omicron S-bearing virus robustly escapes vaccineinduced humoral immunity, mainly due to mutations in the receptor-binding motif (RBM), yet 50 51 unlike naturally occurring Omicron, efficiently replicates in cell lines and primary-like distal lung 52 cells. In K18-hACE2 mice, while Omicron causes mild, non-fatal infection, the Omicron S-53 carrying virus inflicts severe disease with a mortality rate of 80%. This indicates that while the 54 vaccine escape of Omicron is defined by mutations in S, major determinants of viral 55 pathogenicity reside outside of S.

56

57 As of March 2022, the successive waves of the coronavirus disease 2019 (COVID-19) pandemic have been driven by five major SARS-CoV-2 variants, called variants of concern 58 (VOC); Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages), and 59 60 Omicron (BA lineages)⁹. Omicron is the most recently recognized VOC that was first 61 documented in South Africa, Botswana, and in a traveler from South Africa in Hong Kong in November 2021 (GISAID ID: EPI_ISL_7605742)^{10,11}. It quickly swept through the world, 62 displacing the previously dominant Delta variant within weeks and accounting for the majority of 63 new SARS-CoV-2 infections by January 2022¹²⁻¹⁶. Omicron has at least three lineages, BA.1, 64 BA.2, and BA.3, with the former being the most predominant lineage worldwide^{13,17-19}. BA.1 65

(hereinafter referred to as Omicron) exhibits a remarkable escape from infection- and vaccineinduced humoral immunity^{4,5,20,21}. Further, it is less pathogenic than other VOCs in humans and *in vivo* models of infection^{1-3,22-26}. Omicron differs from the prototype SARS-CoV-2 isolate,
Wuhan-Hu-1, by 59 amino acids; 37 of these changes are in the S protein, raising the possibility
that S is at the heart of Omicron's pathogenic and antigenic behavior.

71 Spike mutations only partially affect the replication of Omicron in cell culture

72 The Omicron S protein carries 30 amino acid substitutions, 6 deletions, and one three-73 amino acid-long insertion compared to Wuhan-Hu-1 (Fig. 1a,b). Twenty-five of these changes 74 are unique to Omicron relative to other VOCs, although some of them have been reported in waste water and minor SARS-CoV-2 variants²⁷⁻²⁹. To test the role of the S protein in Omicron 75 phenotype, we generated a chimeric recombinant virus containing the S gene of Omicron (USA-76 Ih01/2021) in the backbone of an ancestral SARS-CoV-2 isolate (GISAID EPI_ISL_2732373)³⁰ 77 78 (Fig. 1c). To produce this chimeric Omi-S virus, we employed a modified form of cyclic 79 polymerase extension reaction (CPER) (Extended Data Fig. 1) that yielded highly concentrated virus stocks, containing 0.5-5 x 10⁶ plague-forming units (PFU) per ml, from transfected cells 80 81 within two days of transfection (Fig. 1d,e), obviating the need for additional viral amplification^{31,32}. 82

We first compared the infection efficiency of Omi-S with an ancestral virus and Omicron in cell culture (**Fig. 2a**). For this, we infected ACE2/TMPRSS2/Caco-2³³ and Vero E6 cells with Omi-S, a recombinant D614G-bearing ancestral virus (GISAID EPI_ISL_2732373)³⁰, and a clinical Omicron isolate (USA-Ih01/2021) at a multiplicity of infection (MOI) of 0.01 and monitored viral propagation by flow cytometry and the plaque assay. The ancestral virus [hereinafter referred to as wild-type (WT)] and Omi-S spread fast in ACE2/TMPRSS2/Caco-2

89 cells, vielding 89% and 80% infected cells, respectively, at 24 hours post-infection (hpi) (Fig. 90 2b). In contrast, Omicron replicated slower, leading to 48% infected cells at 24 hpi. A similar pattern was seen in Vero E6 cells, where 60% and 41% of cells were positive for WT and Omi-91 92 S, respectively, at 48 hpi, in contrast to 10% positive cells for Omicron (Fig. 2c). The plaque 93 assay showed that although both Omi-S and Omicron produced lower levels of infectious virus 94 particles compared with WT, the viral titer of Omi-S was significantly higher than that of 95 Omicron. In ACE2/TMPRSS2/Caco-2 cells, Omi-S produced 5.1-fold (p = 0.0006) and 5.5-fold 96 (p = 0.0312) more infectious particles than Omicron at 12 hpi and 24 hpi, respectively (**Fig. 2d**). 97 Similarly, in Vero E6 cells, the infectious virus titers of Omi-S were 17-fold (p = 0.0080) and 11-98 fold (p = 0.0078) higher than that of Omicron at 24 hpi and 48 hpi, respectively (Fig. 2e). The 99 difference between viruses became less obvious at later time points due to higher cytotoxicity 100 caused by Omi-S compared with Omicron (Fig. 2f). The higher infection efficiency of Omi-S 101 relative to Omicron was also reflected in the plague size; while WT produced the largest plagues 102 (~ 4.1 mm), the size of Omi-S plaques (~2.2 mm) was 2-fold (p < 0.0001) larger than that of 103 Omicron plaques (~1.1 mm) (Fig. 2g). These results indicate that while mutations in the S 104 protein influence the infection efficiency of Omicron, they do not fully explain the infection 105 behavior of Omicron in cell culture.

We next expanded our studies to lung epithelial cells, which are a major viral replication site in patients with severe COVID-19. Accordingly, we employed human induced pluripotent stem cell-derived lung alveolar type 2 epithelial (iAT2) cells. AT2 cells represent an essential cell population in the distal lung and constitute one of the primary targets of SARS-CoV-2 infection³⁴⁻ We infected iAT2 cells, grown as an air-liquid interface (ALI) culture, at an MOI of 2.5 and monitored the secretion of viral progeny on the apical interface of cells at 48 hpi and 96 hpi. In congruence with the results obtained from cell lines, WT SARS-CoV-2 produced the highest levels of infectious virus particles (**Fig. 2h**). Among the Omi-S and Omicron, the former yielded \sim 5-fold (p = 0.0008) higher infectious viral titer at 48 hpi. The viral titers for WT and Omi-S decreased at 96 hpi compared with 48 hpi due to the cytopathic effect (CPE) of infection. However, no CPE was seen for Omicron, leading to sustained production of infectious virions. Overall, these results corroborate the conclusion that mutations in S do not fully account for the attenuated replication capacity of Omicron in cultured human cells.

119 Spike has an appreciable but minimal role in Omicron pathogenicity in K18-hACE2 mice

120 To examine if Omi-S exhibits higher in vivo fitness compared with Omicron, we investigated the infection outcome of Omi-S relative to WT SARS-CoV-2 and Omicron in K18-121 hACE2 mice. In agreement with the published literature^{3,37-39}, intranasal inoculation of mice 122 (aged 12-20 weeks) with Omicron (10⁴ PFU per animal) caused no significant weight loss, 123 whereas inoculation with WT virus triggered a rapid decrease in body weight with all animals 124 125 losing over 20% of their initial body weight by 8 days post-infection (dpi) (Fig. 3a). Importantly, 80% of animals infected with Omi-S also lost over 20% of their body weight by 9 dpi (Fig. 3a 126 and Extended Data Fig. 2a). The evaluation of clinical scores (a cumulative measure of weight 127 128 loss, abnormal respiration, aberrant appearance, reduced responsiveness, and altered 129 behavior) also revealed a similar pattern; while Omicron-infected mice displayed little to no signs 130 of clinical illness, the health of those infected with WT and Omi-S rapidly deteriorated, with the 131 former inflicting a more severe disease (p = 0.0102) (Fig. 3b and Extended Data Fig. 2b). Since SARS-CoV-2 causes fatal infection in K18-hACE2 mice^{3,40,41}, we leveraged this situation 132 133 to compare the animal survival after viral infection. In agreement with the results of body-weight 134 loss and clinical score, WT and Omi-S caused mortality rates of 100% (6/6) and 80% (8/10),

respectively. In contrast, all animals infected with Omicron survived (Fig. 3c). These findings
 indicate that the S protein is not the primary determinant of Omicron's pathogenicity in K18 hACE2 mice.

138 Next, we compared the virus propagation of Omi-S with Omicron and WT SARS-CoV-2 139 in the lungs of K18-hACE2 mice. The mice (12-20 weeks old) were intranasally challenged with 140 10⁴ PFU (7 mice per virus), and their lungs were collected at 2 and 4 dpi for virological and 141 histological analysis. Consistent with in vitro findings, the infectious virus titer in the lungs of WT-142 infected mice was higher than that detected in mice infected with other two viruses (Fig. 3d). 143 Notably however, Omi-S-infected mice produced 30-fold (p = 0.0286) more infectious virus particles compared with Omicron-infected mice at 2 dpi. The titer decreased at 4 dpi for WT-144 145 and Omi-S-infected mice, yet it showed an increasing trend for Omicron-infected animals, 146 pointing to the possibility of mild but persistent infection by Omicron in K18-hACE2 mice.

147 To evaluate the viral pathogenicity in the lungs, we performed histopathological analysis of the lung tissue of infected K18-hACE2 mice. As previously reported^{3,42}, an extensive near-148 149 diffused immunoreactivity of the SARS-CoV-2 S protein was detected in lung alveoli of mice 150 infected with WT virus (Fig. 3e). In contrast, Omi-S and Omicron infection produced localized foci of alveolar staining with fewer foci for Omicron compared with Omi-S. The most striking 151 152 phenotype was seen in bronchiolar epithelium. While Omi-S virus caused a severe bronchiolar 153 infection with around 15-20% of bronchioles being positive for the S protein in all mice examined at 2 dpi, less than 1% bronchioles were S-positive in Omicron-infected mice (Fig. 3f). Further, 154 bronchiolar infection was associated with epithelial necrosis in Omi-S-infected mice, as 155 determined through serial hematoxylin and eosin (H&E) section analysis, whereas no 156 157 histological evidence of airway injury was observed in Omicron-infected mice (Extended Data **Fig. 3**). This suggests that the replication of Omicron in mice lungs, particularly in bronchioles, is substantially attenuated compared with Omi-S, supporting our conclusion that mutations in the S protein are only partially responsible for the attenuated pathogenicity of Omicron.

161 Mutations in the spike RBM are major drivers of Omicron's escape from neutralization

162 Next, we examined if Omi-S captures the immune escape phenotype of Omicron. A large 163 body of literature has demonstrated extensive escape of Omicron from vaccine-induced humoral immunity ^{4,10,43}. We compared the *in vitro* neutralization activity of sera obtained from vaccinated 164 165 individuals against the SARS-CoV-2 Washington isolate (USA-WA1/2020), Omi-S, and 166 Omicron. Sera collected within two months of the second dose of mRNA-1273 (Moderna mRNA vaccine; n = 12) or BNT162b2 (Pfizer-BioNTech mRNA vaccine; n = 12) vaccine were included 167 168 (Extended Data Table 1). We performed a multicycle neutralization assay using a setting in which the virus and neutralizing sera were present at all times, mimicking the situation in a 169 170 seropositive individual. All sera poorly neutralized Omicron, with 11.1-fold (range: 4.4- to 81.2-171 fold; p < 0.0001) lower half-maximal neutralizing dilution (ND₅₀) for Omicron compared with WA1 (Fig. 4a,b). In fact, around 80% of samples failed to completely neutralize Omicron at the 172 173 highest tested concentration (Extended Data Fig. 4). Notably, Omi-S exhibited identical ND₅₀ 174 values to Omicron (11.5-fold lower than that of WA1; p < 0.0001) (Fig. 4a,b), suggesting that 175 the Omicron S protein, when incorporated into a WT virus, behaves the same way as in 176 Omicron.

The SARS-CoV-2 S protein comprises two domains: the S1 domain, which interacts with the ACE2 receptor, and the S2 domain, which is responsible for membrane fusion⁴⁴. Within the S1 domain lie an N-terminal domain (NTD) and a receptor-binding domain (RBD), which harbors the receptor-binding motif (RBM) that makes direct contact with the ACE2 receptor⁴⁵. The NTD

181 of Omicron S carries 11 amino acid changes, including 6 deletions and one three-amino acid-182 long insertion, whereas the RBD harbors 15 mutations, 10 of which are concentrated in the RBM (Fig. 1a,b). Both NTD and RBD host neutralizing epitopes⁴⁶⁻⁵⁰, but the RBD is 183 184 immunodominant and represents the primary target of the neutralizing activity present in SARS-CoV-2 immune sera^{50,51}. To determine if the neutralization resistance phenotype of Omicron is 185 186 caused by mutations in a particular S domain, we generated two groups of chimeric viruses. The 187 first group comprised the WA1 virus carrying the NTD, RBD, or RBM of Omicron (Fig. 4c), and 188 the second group consisted of Omi-S virus bearing the NTD, RBD, or RBM of WA1 (Fig. 4d). The neutralization assay showed that mutations in the RBM were the major cause of Omicron's 189 190 resistance to vaccine-induced humoral immunity: replacing the RBM of WA1 with that of 191 Omicron decreased ND₅₀ by 5.4-fold (p < 0.0001), and conversely, substituting the RBM of Omi-192 S with that of WA1 increased ND₅₀ by 5.6-fold (p = 0.0003) (Fig. 4c.d). The fact that none of the 193 RBM-swap viruses achieved the difference of ~11-fold seen between WA1 and Omi-S suggests 194 that mutations in other parts of S also contribute to vaccine resistance.

195 To investigate if specific mutations in Omicron RBM drive vaccine escape, we 196 generated two additional panels of recombinant viruses, one with WA1 spike carrying Omicron 197 RBM mutations, either singly or in combination (Fig. 4e), and the other with Omicron spike 198 lacking the same set of mutations (Fig. 4f). Two WA1 mutants, mutant 3 (carrying E484A) 199 substitution) and mutant 4 (bearing a cluster of five substitutions Q493R, G496S, Q498R, 200 N501Y, Y505H) exhibited a moderate but statistically significant decrease of 1.4-fold (p =201 0.0002) and 1.8-fold (p = 0.0003) in ND₅₀ values, respectively, compared with WA1 (Fig. 4e). 202 The opposite was observed when these mutations were removed from Omicron S; the Omicron 203 mutant 3 (lacking E484A substitution) and mutant 4 (lacking Q493R, G496S, Q498R, N501Y, Y505H) had a 1.9-fold (p = 0.0082) and 3.1-fold (p = 0.0025) higher ND₅₀ values compared with Omicron (**Fig. 4f**). Since none of the mutants captured the overall phenotype of Omicron, we assume that the vaccine escape is a cumulative effect of mutations distributed along the length of the S protein. It is possible that mutations alter the conformation of Omicron S in such a manner that most of the immunodominant neutralizing epitopes are disrupted and become unavailable for neutralization.

210 **DISCUSSION**

211 This study provides important insights into Omicron pathogenicity. We show that spike, 212 the single most mutated protein in Omicron, has an incomplete role in Omicron attenuation. In in 213 vitro infection assays, the Omicron spike-bearing ancestral SARS-CoV-2 (Omi-S) exhibits much 214 higher replication efficiency compared with Omicron. Similarly, in K18-hACE2 mice, Omi-S contrasts with non-fatal Omicron and causes a severe disease leading to around 80% mortality. 215 This suggests that mutations outside of spike are major determinants of the attenuated 216 217 pathogenicity of Omicron in K18-hACE2 mice. Further studies are needed to identify those 218 mutations and decipher their mechanisms of action.

One potential limitation of our study is the use of K18-hACE2 mice for pathogenesis studies instead of the primate models that have more similarities with humans^{52,53}. It should however be noted that the K18-hACE2 mouse model is a well-established model for investigating the lethal phenotype of SARS-CoV-2^{3,42,54-56}. While these mice develop lung pathology following SARS-CoV-2 infection, mortality has been associated with central nervous system involvement due to viral neuroinvasion^{42,57}. The fact that infection with Omi-S, but not with Omicron, elicits neurologic signs, such as hunched posture and lack of responsiveness, in

K18-hACE2 mice suggests that the neuroinvasion property is preserved in Omi-S, and the determinants of this property lie outside of the spike protein.

228 We found that while the ancestral virus mainly replicates in lung alveoli and causes only 229 rare infection of bronchioles in K18-hACE2 mice, Omi-S with isogenic ancestral virus backbone 230 exhibits higher propensity to replicate in bronchiolar epithelium. This is consistent with a 231 hamster study demonstrating higher predilection of Omicron for bronchioles¹. In vitro studies have also showed that while Omicron replicates poorly in lower lung cells⁵⁸, it causes a robust 232 infection in bronchiolar and nasal epithelial cells⁵⁸⁻⁶⁰. Our findings indicate that the higher 233 preference of Omicron for bronchioles is dictated by mutations in the spike protein. We 234 235 speculate that both Omi-S and Omicron enter the bronchiolar epithelium of K18-hACE2 mice, 236 yet only Omi-S replicates to high enough levels to manifest in overt bronchiolar injury. The 237 preference of Omicron spike for bronchiolar epithelium is likely mediated by its improved efficiency to utilize Cathepsin B/L⁵⁸⁻⁶², which form an active viral entry pathway in bronchioles 238 and other airway cells^{59,63}. In contrast, SARS-CoV-2 entry into alveolar epithelial cells is mainly 239 driven by TMPRSS2^{36,64}, which Omicron spike is deficient in utilizing^{60,65}, leading to poor 240 infection of these cells^{3,37,58,60}. These findings explain the higher transmission and lower lung 241 242 pathology caused by Omicron.

Our study shows that mutations in the RBM of Omicron spike are the major determinants of the viral escape from neutralizing antibodies, although mutations in other regions of spike also contribute. Within the RBM, we identify two hotspots of mutations, which impart on Omicron spike the ability to resist neutralization: one bearing the E484A substitution and the other harboring a cluster of five substitutions, Q493R, G496S, Q498R, N501Y and Y505H. The E484A substitution has been shown to escape neutralization by convalescent sera⁶⁶. Further,

structural modeling suggests that some therapeutic monoclonal antibodies establish highly 249 250 stable salt bridges with the E484 residue, entirely losing their binding when this residue is changed to A or upon Q493K and Y505H changes⁶⁷. Similarly, mapping of RBM residues that 251 252 directly interact with 49 known neutralizing antibodies revealed N440, G446, S477, and T478 as 253 low-frequently interactors, N501, Y505, and Q498 as medium-frequency interactors, and E484 and Q493 as high-frequency interactors⁶⁸, which is in line with our neutralization assay results. 254 Interestingly, while antibody-binding potential of Omicron spike is impaired⁶⁹, its receptor-binding 255 256 capacity is intact. In fact, the Omicron RBD has higher affinity for ACE2 relative to the Wuhan-Hu-1 and Delta RBDs⁶⁰. This indicates that mutations in the Omicron spike have evolved in such 257 258 a manner that they hinder antibody binding but preserve the receptor engagement. This opens 259 up the possibility of targeting the conserved and structurally constrained regions of spike 260 involved in ACE2 recognition for the design of broad-spectrum vaccines to control the current 261 COVID-19 pandemic.

262 MATERIALS AND METHODS

263 Cells, antibodies, and plasmids

The cell lines were incubated at 37°C and 5% CO₂ in a humidified incubator. Human embryonic kidney HEK293T cells (ATCC; CRL-3216), human lung adenocarcinoma A549 cells (ATCC; CCL-185), human colorectal adenocarcinoma Caco-2 cells (ATCC; HTB-37), and African green monkey kidney Vero E6 cells were maintained in DMEM (Gibco; #11995-065) containing 10% FBS and 1X non-essential amino acids. Lentiviral delivery system was used to generate cells stably expressing human ACE2 and TMPRSS2. Mycoplasma negative status of all cell lines was confirmed. Anti-SARS-CoV nucleocapsid (N) protein antibody (Rockland; #200-401-A50) was used for detection of the SARS-CoV-2 N protein by IF. Expression plasmid encoding the spike protein of the SARS-CoV-2 Wuhan isolate, pCSII-SARS-CoV-2 F8, was a kind gift from Yoshiharu Matsuura³². We replaced the Wuhan spike in this plasmid with a chemically synthesized version of Omicron spike and called the resulting plasmid pCSII-SARS-CoV-2 F8_Omicron. The lentiviral vectors, pLOC_hACE2_PuroR and pLOC_hTMPRSS2_BlastR, containing human ACE2 and TMPRSS2, respectively, have been previously described³³.

278 **Omicron stock preparation and titration**

All procedures were performed in a biosafety level 3 (BSL3) facility at the National 279 280 Emerging Infectious Diseases Laboratories of the Boston University using biosafety protocols approved by the institutional biosafety committee (IBC). The SARS-CoV-2 BA.1 Omicron virus 281 stock was generated in ACE2/TMPRSS2/Caco-2 cells. Briefly, 5 x 10⁵ cells, grown overnight in 282 283 DMEM/10%FBS/1X NEAA in one well of a 6-well plate, were inoculated with the collection 284 medium in which the nasal swab from a SARS-CoV-2 patient was immersed. The swab material was obtained from the Department of Public Health, Massachusetts, and it contained the 285 286 sequence-verified Omicron virus (NCBI accession number: OL719310). Twenty-four hours after 287 infecting cells, the culture medium was replaced with 2 ml of DMEM/2%FBS/1X NEAA and the 288 cells were incubated for another 72h, at which point the CPE became visible. The culture 289 medium was harvested, passed through a 0.45 µ filter, and kept at -80°C as a P0 virus stock. To generate a P1 stock, we infected 1 x 10⁷ ACE2/TMPRSS2/Caco-2 cells, seeded the day before 290 in a T175 flask, with the P0 virus at an MOI of 0.01. The next day, the culture medium was 291 292 changed to 25 ml of 2% FBS-containing medium. Three days later, when the cells exhibited excessive CPE, the culture medium was harvested, passed through a 0.45 µ filter, and stored at
-80°C as a P1 stock.

295 To titrate the virus stock, we seeded ACE2/TMPRSS2/Caco-2 cells into a 12-well plate at a density of 2 x 10⁵ cells per well. The next day, the cells were incubated with serial 10-fold 296 297 dilutions of the virus stock (250 µl volume per well) for 1h at 37°C, overlayed with 1 ml per well 298 of medium containing 1:1 mixture of 2X DMEM/4% FBS and 1.2% Avicel (DuPont; RC-581), and 299 incubated at 37°C for another three days. To visualize the plagues, the cell monolayer was fixed 300 with 4% paraformaldehyde and stained with 0.1% crystal violet, with both fixation and staining performed at room temperature for 30 minutes each. The number of plagues were counted and 301 302 the virus titer was calculated.

303 Recombinant SARS-CoV-2 generation by CPER

SARS-CoV-2 recombinant viruses were generated by using a modified form of the 304 recently published CPER protocol^{32,70}. Full-length SARS-CoV-2 cDNA cloned onto a bacterial 305 artificial chromosome (BAC)³⁰ was used as a template to amplify the viral genome into eight 306 307 overlapping fragments (F1, F2, F3, F4, F5, F6, F7, and F9). The pCSII-SARS-CoV-2 F8 and 308 pCSII-SARS-CoV-2 F8 Omicron plasmids, which were used to generate spike mutants, served 309 as templates for amplification of fragment 8 (F8). A UTR linker containing a hepatitis delta virus 310 ribozyme (HDVr), the bovine growth hormone polyadenylation signal sequence (BGH-polyA), 311 and a cytomegalovirus (CMV) promoter was cloned onto a pUC19 vector and used as a 312 template to amplify the linker sequence. The 5' termini of all ten DNA fragments (F1-F9 and the 313 linker) were phosphorylated by using T4 PNK (NEB; #M0201), and the equimolar amounts (0.05 314 pmol each) of the resulting fragments were subjected to a CPER reaction in a 50 µl volume 315 using 2 µl of PrimeStar GXL DNA polymerase (Takara Bio; #R050A). The following cycling

conditions were used for CPER: an initial denaturation at 98°C for 2 min; 35 cycles of denaturation at 98°C for 10 s, annealing at 55°C for 15 s, and extension at 68°C for 15 min; and a final extension at 68°C for 15 min. The nicks in the circular product were sealed by using DNA ligase.

To transfect cells with the CPER product, we seeded ACE2/TMPRSS2/Caco-2 cells into 320 a 6-well plate at a density of 5 x10⁵ cells per well. The transfection mix was prepared by mixing 321 322 26 µl of the original 52 µl CPER reaction volume with 250 µl of Opti-MEM (Thermo Fisher Scientific; #31985070) and 6 µl of TransIT-X2 Dynamic Delivery System (Mirus Bio; #MIR 323 324 6000). Following incubation at room temperature for 25 min, the transfection mix was added to the cells. The next day, the culture medium was replaced with fresh DMEM containing 2% FBS. 325 326 The CPE became visible in 3-4 days, at which point the culture medium was collected and 327 stored as a P0 virus stock. The P0 stock was used for experiments described in this manuscript. 328 The spike region of all CPER-generated viruses was sequenced by either Sanger sequencing or 329 next generation sequencing to confirm the presence of desired and the absence of adventitious 330 changes.

331 SARS-CoV-2 neutralization assay

For neutralization assays, initial 1:10 dilutions of plasma, obtained from individuals who received two shots of either Moderna or Pfizer mRNA-based SARS-CoV-2 vaccine, were five-fold serial diluted in Opti-MEM over seven or eight dilutions. These plasma dilutions were then mixed at a 1:1 ratio with 1.25×10^4 infectious units of SARS-CoV-2 and incubated for 1h at 37°C. Thereafter, 100 µl of this mixture was directly applied to ACE2/A549 cells seeded the previous day in poly-L-lysine-coated 96-well plates at a density of 2.5 x 10^4 cells per well in 100 µl volume. Thus, the final starting dilution of plasma was 1:20 and the final MOI was 0.5. The cells were incubated at 37°C for 24h, after which they were fixed and stained with an anti nucleocapsid antibody. When PBS instead of plasma was used as a negative control, these
 infection conditions resulted in around 40-50% infected cells at 24 hpi.

342 Generation and infection of iAT2 cells

343 The detailed protocol for generation of human iPSC-derived alveolar epithelial type II cells (iAT2s) has been published in our recent papers^{36,71}. The air-liquid interface (ALI) cultures 344 345 were established by preparing single cell suspensions of iAT2 3D sphere cultures grown in 346 Matrigel. Briefly, Matrigel droplets containing iAT2 spheres were dissolved in 2 mg/ml dispase 347 (Sigma) and the spheres were dissociated in 0.05% trypsin (GIBCO) to generate a single-cell 348 suspension. 6.5 mm Transwell inserts (Corning) were coated with dilute Matrigel (Corning) in 349 accordance with the manufacturer's protocol. Single-cell iAT2s were plated on Transwells at a 350 density of 520,000 cells/cm2 in 100 µl of CK+DCI medium containing 10 µM of Rho-associated 351 kinase inhibitor ("Y"; Sigma Y-27632). 600 µl of this medium was added to the basolateral 352 compartment. 24h after plating, the basolateral medium was changed with fresh CK+DCI+Y 353 medium. 48h after plating, the apical medium was aspirated to initiate ALI culture. 72h after 354 plating, basolateral medium was replaced with CK+DCI medium to remove the rho-associated 355 kinase inhibitor. Basolateral medium was changed every two days thereafter. The detailed composition of CK+DCI medium is provided in our previous publications^{36,71}. 356

iAT2 cells in ALI cultures were infected with purified SARS-CoV-2 stock at an MOI of 2.5 based on the titration done on ACE2/TMPRSS2/Caco-2 cells. For infection, 100 μ I of inoculum prepared in 1X PBS (or mock-infected with PBS-only) was added to the apical chamber of each Transwell and incubated for 2h at 37°C followed by the removal of the inoculum and washing of the apical side three times with 1X PBS (100 μ I/wash). The cells were incubated for two or four

days, after which the newly released virus particles on the apical side were collected by adding 100 μl of 1X PBS twice to the apical chamber and incubating at 37°C for 15 min. The number of infectious virus particles in the apical washes were measured by the plaque assay on ACE2/TMPRSS2/Caco-2 cells. For flow cytometry, iAT2 cells were detached by adding 0.2 ml Accutase (Sigma; #A6964) apically and incubated at room temperature for 15 min. The detached cells were pelleted by low-speed centrifugation, fixed in 10% formalin, and stained with anti-SARS-CoV-2 N antibody.

369 Mice maintenance and approvals

370 Mice was maintained in a facility accredited by the Association for the Assessment and 371 Accreditation of Laboratory Animal Care (AAALAC). Animal studies were performed following the recommendations in the Guide for the Care and Use of Laboratory Animals of the National 372 373 Institutes of Health. The protocols were approved by the Boston University Institutional Animal 374 Care and Use Committee (IACUC). Heterozygous K18-hACE2 C57BL/6J mice (Strain 2B6.Cg-375 Tg(K18-ACE2)2Prlmn/J) were purchased from the Jackson Laboratory (Jax, Bar Harbor, ME). 376 Animals were housed in ventilated cages (Tecniplast, Buguggiate, Italy) and maintained on a 377 12:12 light cycle at 30-70% humidity, ad-libitum water, and standard chow diets (LabDiet, St. 378 Louis, MO).

379 Mice infection

Twelve to twenty weeks old male and female K18-hACE2 mice were inoculated intranasally with 10^4 PFU of SARS-CoV-2 in 50 µl of sterile 1X PBS. The inoculations were performed under 1-3% isoflurane anesthesia. Twenty-six mice (6 for WT, 10 for Omi-S, and 10 for Omicron) were enrolled in a 14-day survival study, and another 42 mice (14 for each of the

WT, Omi-S, and Omicron viruses) were used for virological and histological analysis of infected 384 385 lungs. During the survival study, the animals were monitored for body weight, respiration, 386 general appearance, responsiveness, and neurologic signs. An IACUC-approved clinical scoring 387 system was used to monitor disease progression and define humane endpoints. The score of 1 388 was given for each of the following situations: body weight, 10-19% loss; respiration, rapid and 389 shallow with increased effort; appearance, ruffled fur and/or hunched posture; responsiveness, 390 low to moderate unresponsiveness; and neurologic signs, tremors. The sum of these individual 391 scores constituted the final clinical score. Animals were considered moribund and humanly 392 euthanized in case of weight loss greater than or equal to 20%, or if they received a clinical 393 score of 4 or greater for two consecutive days. Body weight and clinical score were recorded 394 once per day for the duration of the study. For the purpose of survival curves, animals 395 euthanized on a given day were counted dead the day after. Animals found dead in cage were 396 counted dead on the same day. For euthanization, an overdose of ketamine was administered 397 followed by a secondary method of euthanization.

398 For quantification of SARS-CoV-2 infectious particles in lungs by the plaque assay, lung 399 tissues were collected in 600 µl of RNAlater stabilization solution (ThermoFisher Scientific: 400 #AM7021) and stored at -80°C until analysis. 20-40 mg of tissue was placed in a tube containing 401 600 µl of OptiMEM and a 5 mm stainless steel bead (Qiagen; #69989) and homogenized in the 402 Qiagen TissueLyser II by two dissociation cycles (1,800 oscillations/minute for 2 minutes) with a 403 one-minute interval between cycles. The homogenate was centrifuged at 15,000 xg for 10 404 minutes at room temperature and the supernatant was transferred to a new tube. Ten-fold serial 405 dilutions of this supernatant were used for the plaque assay on ACE2/TMPRSS2/Caco-2 cells, 406 as described above.

407 For IHC and histologic analysis, the insufflated whole lung tissues were inactivated in 408 10% neutral buffered formalin at a 20:1 fixative to tissue ratio for a minimum of 72h before 409 removal from BSL3 in accordance with an approved IBC protocol. Tissues were subsequently 410 processed, embedded in paraffin and five-micron sections stained with hematoxylin and eosin 411 (H&E) following standard histological procedures. IHC was performed using a Ventana 412 BenchMark Discovery Ultra autostainer (Roche Diagnostics, USA). An anti-SARS-CoV-2 S 413 antibody (Cell Signaling technologies: clone E5S3V) that showed equivalent immunoreactivity 414 against WT and Omicron spike was used to identify virus-infected cells. Negative and positive controls for IHC included blocks of uninfected and SARS-CoV-2-infected Vero E6 cells, 415 416 respectively.

417 Flow cytometry

For flow cytometry, fixed cells were permeabilized in 1x permeabilization buffer (ThermoFisher Scientific; #00-5523-00) and stained with SARS-CoV-2 nucleocapsid antibody (Rockland; #200-401-A50, 1:1,000), followed by donkey anti-rabbit IgG-AF647 secondary antibody (ThermoFisher Scientific; #A-31573). Gating was based on uninfected stained control cells. The extent of staining was quantified using a BD LSR II flow cytometer (BD Biosciences, CA), and the data were analyzed with FlowJo v10.6.2 (FlowJo, Tree Star Inc).

424 Immunofluorescence

Immunofluorescence was performed as described in our previous publication³³. Briefly,
virus-infected cells were fixed in 4% paraformaldehyde and permeabilized in a buffer containing
0.1% Triton X-100 prepared in PBS. Following blocking in a buffer containing 0.1% Triton X-100,
10% goat serum, and 1% BSA, the cells were incubated overnight at 4°C with anti-SARS-CoV

429 Nucleocapsid antibody (1:2,000 dilution). The cells were then stained with Alexa Fluor 568-430 conjugated goat anti-rabbit secondary antibody (1:1000 dilution) (Invitrogen; #A11008) in the 431 dark at room temperature for 1h and counterstained with DAPI. Images were captured using the 432 ImageXpress Micro Confocal (IXM-C) High-Content Imaging system (Molecular Devices) with a 433 4x S Fluor objective lens at a resolution of 1.7 micron/pixel in the DAPI (excitation: 400 nm/40 434 nm, emission: 447 nm/60 nm) and TexasRed (excitation: 570nm/80nm, emission: 624nm/40nm) 435 channels. Both channels were used to establish their respective laser autofocus offsets. The 436 images were analyzed using MetaXpress High Content Image Acquisition and Analysis software 437 (Molecular Devices). First, the images were segmented using the CellScoring module. The 438 objects between 7 and 20 microns in diameter and greater than 1800 gray level units in intensity 439 were identified and classified as nuclei. Positive cells were taken as nuclei having TexasRed 440 signal of 1500 gray level units or above within 10 to 20 microns of each nucleus. The remaining 441 objects were set to negative cells. From these objects, the following readouts were measured 442 and used for downstream analysis: Total number of positive and negative cells, total area of 443 positive cells, and integrated intensity in the TexasRed channel for positive cells. To calculate 444 the 50% neutralizing dilution (ND₅₀), we performed a non-linear regression curve fit analysis 445 using Prism 9 software (GraphPad).

446 **ACKNOWLEDGEMENT**

We thank Dr. Yoshiharu Matsuura from Osaka University, Japan, for providing the pCSII-SARS-CoV-2 F8 plasmid; the Department of Public Health, Massachusetts, for providing the clinical specimen containing Omicron virus; and the ICCB-Longwood Screening Facility of Harvard Medical School for assistance with IF image acquisition and analysis. This work was supported by Boston University startup funds (to MS and FD), Peter Paul Career Development Award (to FD), and BMBF SenseCoV2 01KI20172A (to AE) and DFG Fokus COVID-19, EN 423/7-1 (to AE). The authors would also like to acknowledge the NIH S10 Shared Instrumentation Grants, S10-OD026983 and SS10-OD030269 (to NAC), for supporting this work. We thank the Evans Center for Interdisciplinary Biomedical Research at Boston University School of Medicine for their support of the Affinity Research Collaborative on 'Respiratory Viruses: A Focus on COVID-19'.

458 AUTHORS' STATEMENT ABOUT ACKNOWLEDGEMENT

The acknowledgement section has been updated according to the 2021 NIH guidelines for acknowledging federal funding (<u>https://grants.nih.gov/policy/federal-funding.htm</u>). Based on these guidelines, the authors acknowledge support from two NIH Shared Instrumentation Grants, S10-OD026983 and SS10-OD030269. Funds from these grants were used to purchase shared-use equipment for Boston University core facilities, and this equipment was used in the research described here.

465 **AUTHOR CONTRIBUTIONS**

M.S. conceptualized the study. DYC, AHT, DK, CVC, NK, HLC, FD, and MS performed
experiments. GL and MUG established and provided the modified CPER system. NAC
performed histopathologic and IHC analysis of mouse lungs. SCB and MB provided scientific
input and helped secure funds. AH and AE provided BAC harboring the SARS-CoV-2 genome.
JHC provided the Omicron isolate. YK provided plasma samples. MS wrote the manuscript,
which was read, edited, and approved by all authors.

472 **REFERENCES**

- 473 1 Suzuki, R. *et al.* Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
 474 *Nature*, doi:10.1038/s41586-022-04462-1 (2022).
- 475 2 Halfmann, P. J. *et al.* SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. *Nature*, doi:10.1038/s41586-022-04441-6 (2022).
- 477 3 Shuai, H. *et al.* Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron.
 478 *Nature*, doi:10.1038/s41586-022-04442-5 (2022).
- 479 4 Dejnirattisai, W. *et al.* SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from 480 neutralizing antibody responses. *Cell* **185**, 467-484 e415, doi:10.1016/j.cell.2021.12.046 (2022).
- VanBlargan, L. A. *et al.* An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes
 neutralization by therapeutic monoclonal antibodies. *Nat Med*, doi:10.1038/s41591-021-01678-y
 (2022).
- 484 6 Planas, D. *et al.* Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature*,
 485 doi:10.1038/s41586-021-04389-z (2021).
- 486 7 Liu, L. *et al.* Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.
 487 *Nature*, doi:10.1038/s41586-021-04388-0 (2021).
- 488 8 Hoffmann, M. *et al.* The Omicron variant is highly resistant against antibody-mediated
 489 neutralization: Implications for control of the COVID-19 pandemic. *Cell* 185, 447-456 e411,
 490 doi:10.1016/j.cell.2021.12.032 (2022).
- 491 9 WHO. *Tracking SARS-CoV-2 variants*, https://www.who.int/en/activities/tracking-SARS-CoV-2/variants/ (2022).
- 493 10 Cele, S. *et al.* Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
 494 *Nature* 602, 654-656, doi:10.1038/s41586-021-04387-1 (2022).
- 495 11 Gu, H. *et al.* Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine Hotel, Hong
 496 Kong, China, November 2021. *Emerg Infect Dis* 28, 460-462, doi:10.3201/eid2802.212422
 497 (2022).
- Iuliano, A. D. *et al.* Trends in Disease Severity and Health Care Utilization During the Early
 Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods United States, December 2020-January 2022. *MMWR Morb Mortal Wkly Rep* 71, 146-152,
 doi:10.15585/mmwr.mm7104e4 (2022).
- 50213CDC. COVID Data Tracker, https://covid.cdc.gov/covid-data-tracker/#variant-proportions503(2022).
- 504 14 CoVariants. CoVariants, https://covariants.org (2022).
- 50515Taylor, L. Covid-19: Omicron drives weekly record high in global infections. BMJ 376, 066,506doi:10.1136/bmj.o66 (2022).
- 507 16 Desingu, P. A. & Nagarajan, K. SARS-CoV-2 Omicron variant is spreading in different parts of 508 the world in three different trends. *J Med Virol*, doi:10.1002/jmv.27646 (2022).
- 509 17 WHO. Statement on Omicron sublineage BA.2. (2022).
- 510 18 Desingu, P. A. & Nagarajan, K. Omicron variant losing its critical mutations in the receptor-511 binding domain. *J Med Virol*, doi:10.1002/jmv.27667 (2022).
- 512 19 Desingu, P. A., Nagarajan, K. & Dhama, K. Emergence of Omicron third lineage BA.3 and its 513 importance. *J Med Virol*, doi:10.1002/jmv.27601 (2022).
- Takashita, E. *et al.* Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant.
 N Engl J Med, doi:10.1056/NEJMc2119407 (2022).
- 516 21 Schmidt, F. *et al.* Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *N Engl J Med* 386,
 517 599-601, doi:10.1056/NEJMc2119641 (2022).

- 518 22 ImperialCollegeLondon. *Hospitalisation risk for Omicron cases in England*, 519 (2022).
- Madhi, S. A. *et al.* Population Immunity and Covid-19 Severity with Omicron Variant in South
 Africa. *N Engl J Med*, doi:10.1056/NEJMoa2119658 (2022).
- 523 24 Sigal, A. Milder disease with Omicron: is it the virus or the pre-existing immunity? *Nat Rev* 524 *Immunol* **22**, 69-71, doi:10.1038/s41577-022-00678-4 (2022).
- Wolter, N. *et al.* Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in
 South Africa: a data linkage study. *Lancet* **399**, 437-446, doi:10.1016/S0140-6736(22)00017-4
 (2022).
- 528 26 Dyer, O. Covid-19: Omicron is causing more infections but fewer hospital admissions than delta, 529 South African data show. *BMJ* **375**, n3104, doi:10.1136/bmj.n3104 (2021).
- 530 27 Haseltine, W. A. in Understanding Omicron: Changes In The Spike Protein And Beyond And
 531 What They Portend (2021).
- Smyth, D. S. *et al.* Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater. *Nat Commun* 13, 635, doi:10.1038/s41467-022-28246-3 (2022).
- Kirby, A. E. *et al.* Notes from the Field: Early Evidence of the SARS-CoV-2 B.1.1.529 (Omicron)
 Variant in Community Wastewater United States, November-December 2021. *MMWR Morb Mortal Wkly Rep* 71, 103-105, doi:10.15585/mmwr.mm7103a5 (2022).
- Herrmann, A. *et al.* Cloning of a Passage-Free SARS-CoV-2 Genome and Mutagenesis Using Red
 Recombination. *Int J Mol Sci* 22, doi:10.3390/ijms221910188 (2021).
- 53931Amarilla, A. A. *et al.* A versatile reverse genetics platform for SARS-CoV-2 and other positive-540strand RNA viruses. *Nat Commun* **12**, 3431, doi:10.1038/s41467-021-23779-5 (2021).
- 541 32 Torii, S. *et al.* Establishment of a reverse genetics system for SARS-CoV-2 using circular 542 polymerase extension reaction. *Cell Rep* **35**, 109014, doi:10.1016/j.celrep.2021.109014 (2021).
- 543 33 Chen, D. Y. *et al.* SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway. *J Virol*544 95, e0086221, doi:10.1128/JVI.00862-21 (2021).
- 54534Mulay, A. *et al.* SARS-CoV-2 infection of primary human lung epithelium for COVID-19546modeling and drug discovery. *Cell Rep* **35**, 109055, doi:10.1016/j.celrep.2021.109055 (2021).
- 547 35 Carcaterra, M. & Caruso, C. Alveolar epithelial cell type II as main target of SARS-CoV-2 virus
 548 and COVID-19 development via NF-Kb pathway deregulation: A physio-pathological theory. *Med*549 *Hypotheses* 146, 110412, doi:10.1016/j.mehy.2020.110412 (2021).
- Huang, J. *et al.* SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar
 Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. *Cell Stem Cell* 27, 962973 e967, doi:10.1016/j.stem.2020.09.013 (2020).
- 553 37 Halfmann, P. J. *et al.* SARS-CoV-2 Omicron virus causes attenuated disease in mice and 554 hamsters. *Nature*, doi:10.1038/s41586-022-04441-6 (2022).
- 55538Winkler, E. S. *et al.* SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung556inflammation and impaired function. *Nat Immunol* **21**, 1327-1335, doi:10.1038/s41590-020-0778-5572 (2020).
- Solution Service Service
- 560 40 Cecon, E. *et al.* Therapeutic potential of melatonin and melatonergic drugs on K18-hACE2 mice
 561 infected with SARS-CoV-2. *J Pineal Res* 72, e12772, doi:10.1111/jpi.12772 (2022).

- Lutz, C., Maher, L., Lee, C. & Kang, W. COVID-19 preclinical models: human angiotensinconverting enzyme 2 transgenic mice. *Hum Genomics* 14, 20, doi:10.1186/s40246-020-00272-6
 (2020).
- Mariano Carossino, D. K., Aoife K. O'Connell, Paige Montanaro, Anna E. Tseng, Hans P. Gertje,
 Kyle A. Grosz, Maria Ericsson, Bertrand R. Huber, Susanna A. Kurnick, Saravanan
 Subramaniam, Thomas A. Kirkland, Joel R. Walker, Kevin P. Francis, Alexander D. Klose, Neal
 Paragas, Markus Bosmann, Mohsan Saeed, Udeni B. R. Balasuriya, Florian Douam, Nicholas A.
 Crossland Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only
 Partially Dependent on hACE2 Expression. *Viruses* 14 (2022).
- 57143Ai, J. et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2572variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect 11, 337-343,573doi:10.1080/22221751.2021.2022440 (2022).
- Huang, Y., Yang, C., Xu, X. F., Xu, W. & Liu, S. W. Structural and functional properties of
 SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. *Acta Pharmacol Sin* 41, 1141-1149, doi:10.1038/s41401-020-0485-4 (2020).
- 577 45 Lan, J. *et al.* Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 578 receptor. *Nature* **581**, 215-220, doi:10.1038/s41586-020-2180-5 (2020).
- 579 Cerutti, G. et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal 46 580 domain target single supersite. Cell Host Microbe 29, 819-833 e817. а doi:10.1016/j.chom.2021.03.005 (2021). 581
- 582 47 Chi, X. *et al.* A neutralizing human antibody binds to the N-terminal domain of the Spike protein
 583 of SARS-CoV-2. *Science* 369, 650-655, doi:10.1126/science.abc6952 (2020).
- 58448Voss, W. N. *et al.* Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-585RBD spike epitopes. *Science* **372**, 1108-1112, doi:10.1126/science.abg5268 (2021).
- Premkumar, L. *et al.* The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci Immunol* 5, doi:10.1126/sciimmunol.abc8413 (2020).
- 589 50 Ju, B. *et al.* Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature* 584, 115 590 119, doi:10.1038/s41586-020-2380-z (2020).
- 51 Piccoli, L. *et al.* Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike
 592 Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* 183, 1024-1042
 593 e1021, doi:10.1016/j.cell.2020.09.037 (2020).
- 594 52 Vogel, A. B. *et al.* BNT162b vaccines protect rhesus macaques from SARS-CoV-2. *Nature* 592, 283-289, doi:10.1038/s41586-021-03275-y (2021).
- 596
 53
 Chang, M. C., Hild, S. & Grieder, F. Nonhuman primate models for SARS-CoV-2 research:

 597
 Consider alternatives to macaques. Lab Anim (NY) 50, 113-114, doi:10.1038/s41684-021-00755-6

 598
 (2021).
- 59954Oladunni, F. S. *et al.* Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting600enzyme 2 transgenic mice. Nat Commun 11, 6122, doi:10.1038/s41467-020-19891-7 (2020).
- 55 Yinda, C. K. *et al.* K18-hACE2 mice develop respiratory disease resembling severe COVID-19.
 602 *PLoS Pathog* 17, e1009195, doi:10.1371/journal.ppat.1009195 (2021).
- 603 56 Gan, E. S. *et al.* A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection.
 604 *Antiviral Res* 193, 105138, doi:10.1016/j.antiviral.2021.105138 (2021).
- Kumari, P. *et al.* Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoVin K18-hACE2 Mice. *Viruses* 13, doi:10.3390/v13010132 (2021).

- Hui, K. P. Y. *et al.* SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. *Nature*, doi:10.1038/s41586-022-04479-6 (2022).
- Thomas P. Peacock, J. C. B., Jie Zhou, Nazia Thakur, Joseph Newman, Ruthiran Kugathasan,
 Ksenia Sukhova, Myrsini Kaforou, Dalan Bailey, Wendy S. Barclay. The SARS-CoV-2 variant,
 Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses
 the endosomal route of entry. *bioRxiv*, doi:https://doi.org/10.1101/2021.12.31.474653 (2022).
- 613 60 Meng, B. *et al.* Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. *Nature*, doi:10.1038/s41586-022-04474-x (2022).
- 615 61 Du, X. *et al.* Omicron adopts a different strategy from Delta and other variants to adapt to host. 616 *Signal Transduct Target Ther* **7**, 45, doi:10.1038/s41392-022-00903-5 (2022).
- Pranesh Padmanabhan, N. M. D. Evidence of increased Cathepsin B/L and decreased TMPRSS2 617 62 618 for cell SARS-CoV-2 Omicron usage entry by the variant. bioRxiv, 619 doi:https://doi.org/10.1101/2022.01.13.476267 (2022).
- Kawase, M., Shirato, K., van der Hoek, L., Taguchi, F. & Matsuyama, S. Simultaneous treatment
 of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe
 acute respiratory syndrome coronavirus entry. *J Virol* 86, 6537-6545, doi:10.1128/JVI.00094-12
 (2012).
- 624 64 Grau-Exposito, J. *et al.* Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in 625 human lung tissue cells. *PLoS Pathog* **18**, e1010171, doi:10.1371/journal.ppat.1010171 (2022).
- 626 65 Zhao, H. *et al.* SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity
 627 when compared with Delta variant in TMPRSS2-expressed cells. *Emerg Microbes Infect* 11, 277628 283, doi:10.1080/22221751.2021.2023329 (2022).
- 66 Liu, Z. *et al.* Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. *Cell Host Microbe* 29, 477-488 e474, doi:10.1016/j.chom.2021.01.014
 631 (2021).
- 67 Shah, M. & Woo, H. G. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger
 633 Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies. *Front*634 *Immunol* 12, 830527, doi:10.3389/fimmu.2021.830527 (2021).
- 635 68 Ye, G., Liu, B. & Li, F. Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain.
 636 *Nat Commun* 13, 1214, doi:10.1038/s41467-022-28882-9 (2022).
- 637 69 Carreno, J. M. *et al.* Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
 638 *Nature* 602, 682-688, doi:10.1038/s41586-022-04399-5 (2022).
- Tamura, T. *et al.* Generation and characterization of genetically and antigenically diverse
 infectious clones of dengue virus serotypes 1-4. *Emerg Microbes Infect* 11, 227-239,
 doi:10.1080/22221751.2021.2021808 (2022).
- Jacob, A. *et al.* Derivation of self-renewing lung alveolar epithelial type II cells from human
 pluripotent stem cells. *Nat Protoc* 14, 3303-3332, doi:10.1038/s41596-019-0220-0 (2019).
- 644

645 **FIGURE LEGENDS**

- 646 **Fig. 1: Generating Recombinant SARS-Co-2 by CPER. a,** Schematic overview of mutations in
- 647 Omicron spike (in comparison to the SARS-CoV-2 Wuhan-Hu-1 isolate; NCBI accession
- number: NC_045512). Numbering is based on Wuhan-Hu-1 sequence. Mutations not reported

649 in previous variants of concern are shown in red. NTD, N-terminal domain; RBD, receptor-650 binding domain; RBM, receptor-binding motif. **b**, Location of Omicron mutations on the trimeric spike protein. Domains are colored according to a. c, Schematic of recombinant SARS-CoV-2 651 652 generated by CPER. S, spike; N, nucleocapsid. d, ACE2/TMPRSS2/Caco-2 cells transfected with the SARS-CoV-2 CPER product were stained with an anti-nucleocapsid antibody on 653 indicated days post-transfection. DAPI was used to stain the cell nuclei. NC, negative control 654 655 generated by omitting Fragment 9 from the CPER reaction. e, Virus titer in the culture medium 656 of the transfected cells at indicated days post-transfection, as measured by the plaque assay. 657 The data are plotted as mean \pm SEM of two experimental repeats.

Fig. 2: Effect of spike on in vitro growth kinetics of Omicron. a, Schematic of viruses used 658 in this figure. S, spike; N, nucleocapsid. b-e, ACE2/TMPRSS2/Caco-2 and Vero E6 cells were 659 660 infected at an MOI of 0.01, and the percentage of nucleocapsid (N)-positive cells (n = 6) (**b**,**c**) 661 and levels of infectious virus production (n = 3) (d,e) were determined by flow cytometry and the 662 plaque assay, respectively. f, The cell viability of SARS-CoV-2-infected ACE2/TMPRSS2/Caco-663 2 cells (MOI of 0.1) was quantified by the CellTiter-Glo assay at indicated time points. The P 664 values reflect a statistically significant difference between Omi-S and Omicron. g, Plague sizes. Left, representative images of plaques on ACE2/TMPRSS2/Caco-2 cells. Right, diameter of 665 plagues is plotted as mean ± SD of 20 plagues per virus. h, Human induced pluripotent stem 666 667 cell-derived alveolar type 2 epithelial cells were infected at an MOI of 2.5 for 48h or 96h. The 668 apical side of cells was washed with 1X PBS and the levels of infectious virus particle were 669 measured by the plaque assay. n = 4. Data are mean \pm SD from the indicated number of 670 biological replicates. Experiments were repeated twice, with each experimental repeat 671 containing 2 (**h**) or 3 (**b-g**) replicates. *p* values were calculated by a two-tailed, unpaired *t*-test 672 with Welch's correction. **p* <0.05, ***p* <0.01, ****p* <0.001, and *****p* < 0.0001; ns, not significant.

673 Fig. 3: Role of spike in Omicron pathogenicity. a-c, Male and female K18-hACE2 mice (aged 12-20 weeks) were intranasally inoculated with 1 x 10^4 PFU of WT (n = 6), Omi-S (n = 10), or 674 675 Omicron (n = 10). Two independently generated virus stocks were used in this experiment. The 676 body weight (a), clinical score (b), and survival (c) were monitored daily for 14 days. Animals losing 20% of their initial body weight were euthanized. **d,e,** K18-hACE2 mice were intranasally 677 inoculated with 1 x 10⁴ PFU of WT (n = 7), Omi-S (n = 7), and Omicron (n = 7). Lung samples of 678 679 the infected mice were collected at 2 or 4 dpi to determine the viral titer (n = 4) (d) or for immunohistochemistry (IHC) detection of the S protein (n = 3) (e). In e, representative images of 680 IHC staining for the detection of the SARS-CoV-2 S protein (brown color) in alveoli (arrows) and 681 bronchioles (arrowheads) in the lungs of the infected mice at 2 dpi are shown. (Scale bar = 100 682 683 µm). f, The percentage of S-positive bronchioles in the lungs of infected mice. Each dot 684 represents an infected animal. Data are presented as mean \pm SD from the indicated number of biological replicates. Statistical significance was determined using two-tailed, unpaired t-test 685 686 with Welch's correction (**a,b,d,f**) and log-rank (Mantel-Cox) test (**c**). *p <0.05, **p <0.01, ***p <0.001, and *****p* < 0.0001; ns, not significant. 687

Fig. 4: Role of spike in immune resistance of Omicron. a, ND₅₀ values for WA1, Omi-S, and Omicron in sera from individuals who received two shots of Moderna (donor 1-12) or Pfizer (donor 13-24) vaccine (further details of sera are provided in Extended Data Table 1; individual curves are shown in Extended Data Fig. 4). b, Trajectories of ND₅₀ values against WA1, Omi-S, and Omicron (the data from a is plotted). Fold-change in ND₅₀ values is indicated. **c,d,e,f,** Schematic of the chimeric (**top panels; c,d**) and mutant (**top panels; e,f**) viruses. The amino acid numbering for WA1 mutants in e is based on the WA1 spike sequence, whereas the numbering for Omicron mutants in f is based on the Omicron spike sequence. Six of the 24 sera (three from Moderna and three from Pfizer) were tested. Each serum sample is represented by a dot of specific color. The data are plotted as fold-change of the parental virus. Statistical significance was determined using a two-tailed, unpaired *t* test with Welch's correction. **p* <0.05, ***p* <0.01, ****p* <0.001, and *****p* < 0.0001; ns, not significant.

700 EXTENDED DATA FIGURES

701 Extended Data Fig. 1: Schematic representation of CPER to generate recombinant SARS-


CoV-2. The SARS-CoV-2 genome was amplified into nine overlapping fragments. These fragments and a linker (containing a hepatitis delta virus ribozyme, a poly-A signal, and a CMV promoter) were treated with PNK to phosphorylate 5' ends. The 5'-end phosphorylated fragments were then stitched together by CPER, and the nicks in the resulting circular DNA molecule were closed by treatment with DNA ligase. The CPER product was transfected into cells to rescue virus particles.

Extended Data Fig. 2: Clinical signs of Omi-S-infected mice. K18-hACE2 mice (n = 10) inoculated intranasally with 1 x 10⁴ PFU of Omi-S and described in Fig. 3a-c were monitored for body weight (**a**) and clinical score (**b**). Animals losing 20% of their body weight (8 out of 10) were euthanized. The surviving animals did not show any signs of distress.


Extended Data Fig. 3: Lung pathology induced by Omi-S. The lungs of the male and female K18-hACE2 mice intranasally inoculated with 1 x 10^4 PFU of WT, Omi-S, and Omicron were collected at 2 dpi for histological analysis. **a**, Representative images of hematoxylin and eosin (H&E) staining for the detection of bronchiolar damage in the lungs of the infected mice. The bronchiolar epithelial necrosis is shown with arrows. Note that the necrosis was no longer

722	data presented in Fig. 4a,b are shown. The data represent the mean ± SD of three technical
721	Extended Data Fig. 4: Individual neutralization data. Individual neutralization curves for the
720	bronchiole. (Scale bar = 100 μm).
719	bronchiole found to be positive for Omicron is shown. No evidence of necrosis was seen for this
718	SARS-CoV-2 S protein in the same area where bronchiolar necrosis was seen. The only
717	evident at 4 dpi in any cohort. b, Immunohistochemistry (IHC) staining for the detection of

- replicates. The curves were calculated based on a non-linear regression curve fit analysis in
- Prism. The dotted lines represent the limit of detection.
- 725 Extended Data Table 1: Overview of serum samples used for the analysis of antibody 726 neutralization of WA1, Omi-S, and Omicron. *Days after the second vaccine shot. **The spike 727 antibody titer was measured by Abbott's SARS-CoV-2 immunoassays.
- 728
- 729
- 730




Days post-transfection




Hours post-infection

40 90 Hours post-infection


Fig. 3






bioRxiv preprint doi: https://doi.org/10.1101/2022.10.13.512134; this version posted January 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Extended Data Fig. 1




Extended Data Fig. 2




Omicron







b



bioRxiv preprint doi: https://doi.org/10.1101/2022.10.13.512134; this version posted January 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Extended Data Table 1

Serum no.	Sex	Race	Age	Days post- vaccination*	Vaccine (Manufacturer)	Spike Ab titer (AU/ml)**
1	Male	White	59	18	mRNA-1273 (Moderna)	39823.0
2	Male	Black	26	37	mRNA-1273 (Moderna)	26978.7
3	Male	Asian	55	34	mRNA-1273 (Moderna)	24880.7
4	Male	White	39	32	mRNA-1273 (Moderna)	23816.7
5	Male	Asian	45	38	mRNA-1273 (Moderna)	21659.5
6	Male	White	30	32	mRNA-1273 (Moderna)	18986.5
7	Female	Asian	47	35	mRNA-1273 (Moderna)	100000.0
8	Female	White	62	47	mRNA-1273 (Moderna)	69680.0
9	Female	White	39	14	mRNA-1273 (Moderna)	54996.6
10	Female	White	38	32	mRNA-1273 (Moderna)	46494.7
11	Female	White	34	30	mRNA-1273 (Moderna)	43784.0
12	Female	White	57	42	mRNA-1273 (Moderna)	42140.5
13	Male	Mixed	28	51	BNT162b2 (Pfizer-BioNTech)	17623.8
14	Male	White	30	54	BNT162b2 (Pfizer-BioNTech)	16154.5
15	Male	White	29	54	BNT162b2 (Pfizer-BioNTech)	14261.5
16	Male	Asian	48	48	BNT162b2 (Pfizer-BioNTech)	10593.6
17	Male	White	46	60	BNT162b2 (Pfizer-BioNTech)	9752.3
18	Male	White	31	53	BNT162b2 (Pfizer-BioNTech)	8715.2
19	Female	White	55	52	BNT162b2 (Pfizer-BioNTech)	100000.0
20	Female	White	43	47	BNT162b2 (Pfizer-BioNTech)	44385.4
21	Female	White	56	48	BNT162b2 (Pfizer-BioNTech)	39998.5
22	Female	Mixed	44	49	BNT162b2 (Pfizer-BioNTech)	31141.9
23	Female	White	56	50	BNT162b2 (Pfizer-BioNTech)	25969.6
24	Female	White	55	51	BNT162b2 (Pfizer-BioNTech)	23539.1